Explore

2nd Dermatology Drug Development Summit Europe

2nd Dermatology Drug Development Summit Europe 2020

Scandic Frankfurt Museumsufer, 44 Wilhelm-Leuschner-Straße, Frankfurt am Main, Hessen, 60329, Germany
18 - 20 May 2020
The conference ended on 20 May 2020

Important Dates

Abstract Submission Deadline
17th May 2020

About 2nd Dermatology Drug Development Summit Europe

The only industry-led meeting on the techniques to advance the development and commercialisation of dermatological medicines.

Topics

Medicine, Health, Dermatology

Call for Papers

Following a successful launch in Europe last year, the 2nd Dermatology Drug Development Summit Europe, returns to Frankfurt, Germany on 18-20 May. 

This year’s summit delivers an unrivalled prospect to industry experts in the dermatology space to examine methods to tackle key challenges and review opportunities in developing and bringing to market pioneering dermatology medicines.

Join peers and leaders in this space for an exclusive three-day meeting of comprehensive discussion, sharing of latest advances and pioneering insights, and networking opportunities.

Early booking and group discounts apply, start-up and academic rates are available - see the website for details.

Prices:

Industry Rate - Conference + 1 Workshop: EUR 2898.0,

Industry Rate - Conference Only: EUR 2399.0,

Industry Rate - Workshop Only: EUR 599.0,

Academic/Start-up Rate - Conference + 1 Workshop: EUR 1798.0,

Academic/Start-up Rate - Conference Only: EUR 1499.0,

Academic/Start-up Rate - Workshop Only: EUR 399.0,

Solution Providers - Conference + 1 Workshop: EUR 2798.0,

Solution Providers - Conference Only: EUR 2399.0

Speakers: Angelo Secci, Chief Medical Officer, Vyome Therapeutics Inc., Bernat Vidal, External Research and Innovation Manager, Almirall, Betsy Hughes-Formella, Independent Consultant, Dermatology Drug Development, Charles Evans, Vice President, Pharmaceutical Development, MedPharm, Christian Antoni, Head of Development, Leo-Pharma, Dirk Brockstedt, Chief Scientific Officer, RAPT Therapeutics, Frank Sinner, Institute for Biomedicine and Health Sciences, Joanneum Research, Iain Stuart, Chief Scientific Officer, Foamix Pharmaceuticals, Jakob Felding, Director, Skin Research, LEO Pharma, Janet Konig, Head, Unit on Anesthesiology/ Algesiology/Rheumatology/ Pulmonology/ENT, BfArM, Jean-Francois Ginglinger, Chief Scientific Officer, Temisis Therapeutics, John M. Armstrong, Head of Discovery, Prescription, Galderma, Julien Seneschal, Professor of Dermatology, Bordeaux University, Kendall Marcus, Director, Division of Dermatology and Dental Products, FDA, Matthew Callahan, Founder and Board Director, Botanix, Mehdi Rashighi, Assistant Professor of Dermatology and Director, Connective Tissue Disease Clinic and Research Center, University of Massachusetts Medical School (UMMS), Narasimha Murthy, Professor Pharmaceutics and Drug Delivery, University of Mississippi, Ofer Toledano, Vice President, Research and Development, Sol-Gel Technologies, Rasmus Hogreffe, Head of Virtual Clinical Trials, LEO Innovation Lab, Robert Rissman, Research Director, Dermatology Center for Human Drug Research, Sylvie Gabriel, Head of Market Access, Pricing and HEOR, Galderma, Yiumo Chan, Senior Director, TWi Biotechnology, Inc, Representative, Menlo Therapeutics Inc.

Time: 9:00 am to 5:30 pm

Keep Up to Date with PaperCrowd

Sign up and follow your favorite conferences.

We are no longer accepting conference submissions on PaperCrowd. We apologise for any inconvenience.